Phase I dose escalation study of oral administration of S 78454 given as monotherapy in the treatment of patients with refractory or relapsed acute myeloid leukemia, acute lymphoblastic leukemia or high or intermediary-2 risk myelodysplastic syndrome

Trial Profile

Phase I dose escalation study of oral administration of S 78454 given as monotherapy in the treatment of patients with refractory or relapsed acute myeloid leukemia, acute lymphoblastic leukemia or high or intermediary-2 risk myelodysplastic syndrome

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2015

At a glance

  • Drugs Abexinostat (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Pharmacyclics; Servier
  • Most Recent Events

    • 17 Dec 2015 Status changed from active, no longer recruiting to completed as per ISRCTN: Current Controlled Trials.
    • 31 Mar 2015 Status changed from completed to active, no longer recruiting as per ISRCTN: Current Controlled Trials.
    • 13 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top